Quest Partners LLC Has $77,000 Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Quest Partners LLC lowered its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 66.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,905 shares of the company’s stock after selling 17,982 shares during the quarter. Quest Partners LLC’s holdings in EyePoint Pharmaceuticals were worth $77,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Ameritas Investment Partners Inc. grew its holdings in EyePoint Pharmaceuticals by 44.0% during the first quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company’s stock valued at $77,000 after purchasing an additional 1,136 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of EyePoint Pharmaceuticals by 271.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock valued at $95,000 after buying an additional 7,953 shares during the period. Arizona State Retirement System increased its position in shares of EyePoint Pharmaceuticals by 9.7% in the 2nd quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $115,000 after buying an additional 1,171 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in EyePoint Pharmaceuticals by 129.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,393 shares of the company’s stock worth $194,000 after buying an additional 5,308 shares during the period. Finally, ProShare Advisors LLC bought a new position in EyePoint Pharmaceuticals during the first quarter worth about $209,000. 99.41% of the stock is currently owned by institutional investors.

EyePoint Pharmaceuticals Trading Down 0.7 %

Shares of EYPT stock opened at $8.78 on Wednesday. The firm’s fifty day moving average price is $8.89 and its two-hundred day moving average price is $13.22. EyePoint Pharmaceuticals, Inc. has a 1 year low of $5.67 and a 1 year high of $30.99. The firm has a market capitalization of $469.91 million, a P/E ratio of -4.82 and a beta of 1.59.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.03). The company had revenue of $9.48 million for the quarter, compared to the consensus estimate of $11.61 million. EyePoint Pharmaceuticals had a negative return on equity of 43.24% and a negative net margin of 172.29%. As a group, equities research analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on EYPT. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, June 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of EyePoint Pharmaceuticals in a research note on Thursday, June 20th. Chardan Capital reissued a “buy” rating and set a $28.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Friday, June 28th. JPMorgan Chase & Co. cut their price objective on shares of EyePoint Pharmaceuticals from $32.00 to $29.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. Finally, StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a report on Thursday, September 5th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $30.57.

Insider Activity

In other EyePoint Pharmaceuticals news, Director David R. Guyer sold 11,625 shares of the company’s stock in a transaction on Friday, July 12th. The shares were sold at an average price of $10.06, for a total transaction of $116,947.50. Following the sale, the director now directly owns 1,850 shares of the company’s stock, valued at $18,611. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.74% of the stock is currently owned by insiders.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.